Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Songling Xuemaikang Capsules in Grade 1 Hypertension
NCT06093932Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of songling xuemaikang in essential hypertension, sponsored by Xiyuan Hospital. Started Apr 2024; status: recruiting.
02
Drugs
songling xuemaikang
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06093932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093932.